OTCMKTS:BRTX

BioRestorative Therapies - BRTX Stock Forecast, Price & News

$3.23

+0.25 (+8.39%)

(As of 09/30/2022 12:00 AM ET)

Add

Compare

Today's Range: $2.98
▼
$3.39
50-Day Range: $2.46
▼
$3.40
52-Week Range: $2.46
▼
$24.00

Volume: 59,387 shs
Average Volume: 15,577 shs
Market Capitalization: $11.79 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $37.00

BioRestorative Therapies MarketRank™ Forecast

Analyst Rating: Buy
3.00 Rating Score
Upside/Downside: 1,045.5% Upside
$37.00 Price Target
Short Interest: N/A
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: 0.90
Based on 5 Articles This Week
Insider Trading: Acquiring Shares
$24,258 Bought Last Quarter
Proj. Earnings Growth: Decreasing
From ($2.14) to ($2.42) Per Share

Overall MarketRank^™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.30 out of 5 stars

3.5

Analyst's Opinion

Consensus Rating
BioRestorative Therapies has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 buy ratings, no hold ratings, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $37.00, BioRestorative Therapies has a forecasted upside of 1,045.5% from its current price of $3.23.
Amount of Analyst Coverage
BioRestorative Therapies has only been the subject of 1 research reports in the past 90 days.

N/A

Short Interest

Short Interest
There is no current short interest data available for BRTX.

0.0

Dividend Strength

Dividend Yield
BioRestorative Therapies does not currently pay a dividend.
Dividend Growth
BioRestorative Therapies does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for BRTX.

3.3

News and Social Media Coverage

News Sentiment
BioRestorative Therapies has a news sentiment score of 0.90. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.
News Coverage This Week
MarketBeat has tracked 5 news articles for BioRestorative Therapies this week, compared to 1 article on an average week.
Search Interest
1 people have searched for BRTX on MarketBeat in the last 30 days.
MarketBeat Follows
1 people have added BioRestorative Therapies to their MarketBeat watchlist in the last 30 days.

3.3

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, BioRestorative Therapies insiders have bought more of their company's stock than they have sold. Specifically, they have bought $24,258.00 in company stock and sold $0.00 in company stock.
Percentage Held by Insiders
27.50% of the stock of BioRestorative Therapies is held by insiders. A high percentage of insider ownership can be a sign of company health.
Percentage Held by Institutions
Only 31.66% of the stock of BioRestorative Therapies is held by institutions.

0.6

Earnings and Valuation

Earnings Growth
Earnings for BioRestorative Therapies are expected to decrease in the coming year, from ($2.14) to ($2.42) per share.
Price to Book Value per Share Ratio
BioRestorative Therapies has a P/B Ratio of 0.52. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

About BioRestorative Therapies (OTCMKTS:BRTX) Stock

BioRestorative Therapies, Inc., a life sciences company, focuses on the development of regenerative medicine products and therapies using cell and tissue protocols primarily involving adult stem cells. The company's two core developmental programs relate to the treatment of disc/spine disease and metabolic disorders. Its disc/spine program (brtxDisc) includes a lead cell therapy candidate, BRTX-100, a product candidate formulated from autologous cultured mesenchymal stem cells collected from the patient's bone marrow, which has completed Phase 1 clinical trials for use in the non-surgical treatment of painful lumbosacral disc disorders. The company is also developing Metabolic Program (ThermoStem), a cell-based therapy candidate that is in preclinical stage to target obesity and metabolic disorders using brown adipose derived stem cells to generate brown adipose tissue. In addition, it provides investigational curved needle device designed to deliver cells and/or other therapeutic products or material to the spine and discs. BioRestorative Therapies, Inc. has a research and development agreement with Rohto Pharmaceutical Co., Ltd.; a research agreement with Pfizer, Inc.; and a research collaboration agreement with the University of Pennsylvania. The company was formerly known as Stem Cell Assurance, Inc. and changed its name to BioRestorative Therapies, Inc. in August 2011. BioRestorative Therapies, Inc. was incorporated in 1997 and is based in Melville, New York.

Receive BRTX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for BioRestorative Therapies and its competitors with MarketBeat's FREE daily newsletter.

BRTX Stock News Headlines

October 1, 2022 | americanbankingnews.com

BioRestorative Therapies (OTCMKTS:BRTX) Coverage Initiated at Maxim Group

September 28, 2022 | finance.yahoo.com

BioRestorative Therapies to Present at the Dawson James Securities 7th Annual Small Cap Growth Conference

September 27, 2022 | finance.yahoo.com

BioRestorative Therapies to Participate in the Roth Inaugural Healthcare Opportunities Conference

September 21, 2022 | forbes.com

Best Online Therapy Of 2022

September 7, 2022 | nz.finance.yahoo.com

BioRestorative Therapies to Present at the H.C. Wainwright 24th Annual Global Investment Conference on September 14

September 7, 2022 | finance.yahoo.com

BioRestorative Therapies to Present at the H.C. Wainwright 24th Annual Global Investment Conference on September 14

September 1, 2022 | finance.yahoo.com

Obesity And Back Pain: BioRestorative Therapies Inc. Is Working To Address 2 Common Ailments That Plague Americans with a Major Near Term Data Catalyst

August 31, 2022 | benzinga.com

Major Catalyst Near Term

August 25, 2022 | finance.yahoo.com

Giving Metabolism A Boost? BioRestorative Uses Science Surrounding Brown Fat Cells To Provide A Possible Breakthrough In Metabolic Disorders

August 16, 2022 | finance.yahoo.com

BioRestorative Therapies, Inc. (BRTX)

June 30, 2022 | seekingalpha.com

BioRestorative begins enrollment in mid-stage study of stem cell therapy for lumbar disk disease

June 30, 2022 | finance.yahoo.com

BioRestorative Therapies Announces First Patient Enrolled for the Company’s Phase 2 Clinical Trial to Treat Chronic Lumbar Disc Disease (cLDD)

June 22, 2022 | finance.yahoo.com

EXCLUSIVE: BioRestorative Selects Second Site For Its Lumbar Disc Disease Study

June 22, 2022 | finance.yahoo.com

BioRestorative Therapies Announces Clinical Trial Contract with Second Site for the Company’s Phase 2 Clinical Trial to Treat Chronic Lumbar Disc Disease (cLDD)

April 29, 2022 | finance.yahoo.com

BioRestorative Therapies Hosts Principal Investigator Meeting for its BRTX-100® Phase 2 Clinical Trial to Treat Chronic Lumbar Disc Disease

April 18, 2022 | finance.yahoo.com

BioRestorative Therapies Announces Selection of 10 Clinical Sites for its Phase 2 Clinical Trial to Treat Chronic Lumbar Disc Disease

April 12, 2022 | nasdaq.com

Tuesday 4/12 Insider Buying Report: BRTX, WMC

April 4, 2022 | finance.yahoo.com

BioRestorative Therapies Announces cGMP Cell Manufacturing Facility Certification

March 10, 2022 | finance.yahoo.com

BioRestorative Therapies Announces Research Collaboration with Professor Tore Bengtsson to Evaluate Heat Production of its ThermoStem® Program

February 16, 2022 | seekingalpha.com

BioRestorative Therapies gets US patent related to BRTX-100 disc program

February 16, 2022 | finance.yahoo.com

BioRestorative Therapies Announces Notice of Allowance on Key Patent for its BRTX-100® Disc Program

February 7, 2022 | nasdaq.com

BioRestorative Therapies, Inc. Rings The Nasdaq Stock Market Closing Bell

February 7, 2022 | seekingalpha.com

BioRestorative begins site selection for phase 2 trial in chronic lumbar disc disease

February 7, 2022 | finance.yahoo.com

BioRestorative Therapies Announces it has Initiated its Phase 2 Clinical Trial to Treat Chronic Lumbar Disc Disease – Site Selection Underway

February 7, 2022 | finance.yahoo.com

BioRestorative Therapies to Ring Nasdaq Stock Market Closing Bell

See More Headlines

30 days | 90 days | 365 days | Advanced Chart

Receive BRTX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for BioRestorative Therapies and its competitors with MarketBeat's FREE daily newsletter.

BRTX Company Calendar

Last Earnings: 8/15/2022
Today: 10/01/2022
Fiscal Year End: 12/31/2022

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: OTCMKTS
Industry: Miscellaneous health & allied services, not elsewhere classified
Sub-Industry: N/A
Sector: Medical
Current Symbol: OTCMKTS:BRTX
CUSIP: N/A
CIK: 1505497
Web: www.biorestorative.com
Phone: (631) 760-8100
Fax: N/A
Employees: 5
Year Founded: N/A

Price Target and Rating

Average Stock Price Forecast: $37.00
High Stock Price Forecast: $37.00
Low Stock Price Forecast: $37.00
Forecasted Upside/Downside: +1,045.5%
Consensus Rating: Buy
Rating Score (0-4): 3.00
Research Coverage: 2 Analysts

Profitability

EPS (Most Recent Fiscal Year): N/A
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-44,300,000.00
Net Margins: -34,060.00%
Pretax Margin: -34,078.00%
Return on Equity: -245.85%
Return on Assets: -209.64%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 29.46
Quick Ratio: 29.46

Sales & Book Value

Annual Sales: $50,000.00
Price / Sales: 235.79
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $6.18 per share
Price / Book: 0.52

Miscellaneous

Outstanding Shares: 3,650,000
Free Float: 2,645,000
Market Cap: $11.79 million
Optionable: Not Optionable
Beta: 70.52

Key Executives

Mr. Lance Alstodt (Age 51)
Chairman, Pres & CEO
Comp: $275k

Mr. Francisco J. Silva (Age 47)
Chief Scientist, VP of R&D, Sec. and Director
Comp: $259.38k

Mr. Robert Eugene Kristal (Age 54)
Chief Financial Officer

Mr. Robert Paccasassi (Age 53)
VP of Quality Assurance & Regulatory Compliance

Dr. Wayne J. Olan M.D.
Clinical Director of Regenerative Disc & Spine Program and Member of Scientific Advisory Board

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

BRTX Stock - Frequently Asked Questions

Should I buy or sell BioRestorative Therapies stock right now?: 2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for BioRestorative Therapies in the last twelve months. There are currently 2 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" BRTX shares.
View BRTX analyst ratings or view top-rated stocks.
What is BioRestorative Therapies' stock price forecast for 2022?: 2 Wall Street research analysts have issued 12 month price targets for BioRestorative Therapies' shares. Their BRTX share price forecasts range from $37.00 to $37.00. On average, they expect the company's stock price to reach $37.00 in the next year. This suggests a possible upside of 1,045.5% from the stock's current price.
View analysts price targets for BRTX or view top-rated stocks among Wall Street analysts.
How have BRTX shares performed in 2022?: BioRestorative Therapies' stock was trading at $4.34 on January 1st, 2022. Since then, BRTX shares have decreased by 25.6% and is now trading at $3.23.
View the best growth stocks for 2022 here.
How were BioRestorative Therapies' earnings last quarter?: BioRestorative Therapies, Inc. (OTCMKTS:BRTX) issued its quarterly earnings results on Monday, August, 15th. The company reported ($1.28) earnings per share for the quarter, missing the consensus estimate of ($0.55) by $0.73. The firm earned $0.07 million during the quarter. BioRestorative Therapies had a negative net margin of 34,060.00% and a negative trailing twelve-month return on equity of 245.85%.

When did BioRestorative Therapies' stock split?: Shares of BioRestorative Therapies reverse split on the morning of Wednesday, October 27th 2021. The 1-4000 reverse split was announced on Wednesday, October 27th 2021. The number of shares owned by shareholders was adjusted after the market closes on Wednesday, October 27th 2021. An investor that had 100 shares of stock prior to the reverse split would have 0 shares after the split.
What other stocks do shareholders of BioRestorative Therapies own?: Based on aggregate information from My MarketBeat watchlists, some companies that other BioRestorative Therapies investors own include Co-Diagnostics (CODX), Sierra Oncology (SRRA), Tonix Pharmaceuticals (TNXP), iBio (IBIO), Inovio Pharmaceuticals (INO), PharmaCyte Biotech (PMCB), Vaxart (VXRT), Actinium Pharmaceuticals (ATNM), Inpixon (INPX) and OPKO Health (OPK).
What is BioRestorative Therapies' stock symbol?: BioRestorative Therapies trades on the OTCMKTS under the ticker symbol "BRTX."
How do I buy shares of BioRestorative Therapies?: Shares of BRTX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.
What is BioRestorative Therapies' stock price today?: One share of BRTX stock can currently be purchased for approximately $3.23.
How much money does BioRestorative Therapies make?: BioRestorative Therapies (OTCMKTS:BRTX) has a market capitalization of $11.79 million and generates $50,000.00 in revenue each year.
How can I contact BioRestorative Therapies?: BioRestorative Therapies' mailing address is 40 MARCUS DRIVE, MELVILLE NY, 11747. The official website for the company is www.biorestorative.com. The company can be reached via phone at (631) 760-8100 or via email at ir@biorestorative.com.

This page (OTCMKTS:BRTX) was last updated on 10/1/2022 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

BioRestorative Therapies - BRTX Stock Forecast, Price & News

BioRestorative Therapies MarketRank™ Forecast

Overall MarketRank™

Analyst's Opinion

Short Interest

Short Interest

Dividend Strength

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score

News and Social Media Coverage

News Sentiment

News Coverage This Week

Search Interest

MarketBeat Follows

Company Ownership

Earnings and Valuation

About BioRestorative Therapies (OTCMKTS:BRTX) Stock

BRTX Stock News Headlines

BRTX Company Calendar

Industry, Sector and Symbol

Price Target and Rating

Profitability

Debt

Sales & Book Value

Miscellaneous

Key Executives

Key Competitors

Insiders & Institutions

BRTX Stock - Frequently Asked Questions

MarketBeat Resources

Premium Research Tools

Market Data and Calendars

Investing Education and Resources

Overall MarketRank^™